Targets › IL12A
3 programs from 3 companies in 16 trials: 7 Phase 2, 5 Phase 1, 3 Phase 4, 1 Phase 3; Oncology, Immunology, Metabolic and endocrine; next expected readout Dec 2026.
Heterodimerizes with IL12B to form the IL-12 cytokine or with EBI3/IL27B to form the IL-35 cytokine. IL-12 is primarily produced by professional antigen-presenting cells (APCs) such as B-cells and dendritic cells (DCs) as well as macrophages and granulocytes and regulates T-cell and natural killer-cell responses, induces the production of interferon-gamma (IFN-gamma), favors the differentiation of T-helper 1 (Th1)…. (UniProt, P29459)
Open in Phaseline: the race on IL12A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Johnson & Johnson (Janssen) | Ustekinumab Interleukin-12 inhibitor; Interleukin-23 inhibitor | IL12B, IL12A, IL23A | Phase 3 | Crohn Disease; Psoriasis; Crohn Disease (CD); Type 1 Diabetes Mellitus … | Sep 2027 |
| University Health Network, Toronto | ICG dye Interleukin-12 produced by genetically modified AML cells; immune stimulatory cytokine | IL12A, IL12B | Phase 2 | All Solid Tumors; Surgery Site Fistula; Acute Myeloid Leukemia; Melanoma (Skin) | Dec 2026 |
| Philogen | IL12-L19L19 Antibody-cytokine fusion protein; IL-12 fused to L19 antibody targeting fibronectin | IL12A, IL12B, FN1 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
Crohn Disease (2) Psoriasis (2) Advanced Solid Tumor (1) Crohn Disease (CD) (1) Type 1 Diabetes Mellitus (1) Skin Inflammation (1) Cancer (1) Hematologic and Lymphocytic Disorder (1) Ulcerative Colitis (1) Crohn's Disease (1) All Solid Tumors (1) Surgery Site Fistula (1)
protein or peptide (1), antibody (1)
Philogen (1) Johnson & Johnson (Janssen) (1) University Health Network, Toronto (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.